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Abstract Topical calcineurin inhibitors (TCIs), com-
mercially available since 2000–2001, are the first and only
topical medications approved for chronic treatment of
atopic dermatitis (AD) in pediatric patients and remain a
welcomed alternative to topical corticosteroids. In January
2006, the US Food and Drug Administration (FDA) issued
a boxed warning requirement based on a theoretical risk of
malignancy (including lymphoma) with TCI use. However,
in the years since, analyses of epidemiologic and clinical
data have failed to demonstrate a causal relationship
between TCI use and malignancy or lymphoma risk,
especially for pimecrolimus cream. In fact, the observed
number of malignancies and lymphomas observed both in
post-marketing surveillance and reported to the FDA using
its adverse events reporting system is much lower among
TCI-exposed patients than the expected number for the
general population. Furthermore, among children enrolled
in post-marketing pediatric registry studies for both
tacrolimus and pimecrolimus followed for up to 5.5 years
[10,724 patient-years (PY)] or 6.5 years (16,219 PY),
respectively, the observed number of malignancies and
lymphomas is very low and similar to the number expected
for a sample of similar size in the general population. In
addition to reporting these comparative malignancy and
lymphoma data, this article provides a historical overview
of the boxed warning requirement and critically evaluates
the preclinical, clinical, and epidemiological evidence that
has thus far failed to substantiate a relationship between
TCI use and malignancy. The authors also provide practical
clinical advice for optimizing AD management and patient
care in the context of the boxed warning.
1 Introduction
Topical tacrolimus ointment and pimecrolimus cream have
been commercially available for more than a decade and
are the first and only drugs approved for chronic treatment
of atopic dermatitis (AD) in pediatric patients. These top-
ical calcineurin inhibitors (TCIs) have been a welcomed
alternative to topical corticosteroids because their chronic
use is not associated with skin barrier compromise or
increasing percutaneous absorption. However, in January
2006, the US Food and Drug Administration (FDA) insti-
tuted a boxed warning for both TCIs based on a theoretical
risk of malignancy (including lymphomas) that sparked an
ongoing debate over the safety of these drugs. Since then,
despite a number of epidemiological and clinical studies,
no clear link between TCI use and lymphoma risk has been
established. Yet, the boxed warning remains, leaving many
physicians hesitant to prescribe TCIs and countless patients
(including infants and children) exposed to other anti-
inflammatory agents with proven adverse effects. This
review will (1) present a historical overview of the basis for
the boxed warning, (2) review and critically evaluate the
evidence for lymphoma risk, (3) provide practical clinical
and evidence-based advice on using TCIs in the manage-
ment of AD, and (4) offer advice on addressing obstacles to
patient access to these drugs.
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2 Background
2.1 Regulatory History of the Boxed Warning for TCIs
Tacrolimus ointment 0.03 and 0.1 % [Protopic; owned
and developed by Fujisawa (now Astellas)] and pimecrol-
imus cream 1 % (Elidel; developed by Novartis, Meda
acquired global rights to Elidel in 2011 and immediately
licensed North American rights to Valeant) are TCIs,
which inhibit transcription and release of inflammatory
cytokines and mediators from T cells [1]. In December
2000, tacrolimus ointment was approved for ‘‘short-term
and intermittent long-term therapy in the treatment of
patients (C2 years of age) with moderate to severe AD in
whom the use of alternative, conventional therapies is
deemed inadvisable because of potential risks, or in the
treatment of patients who are not adequately responsive to
or are intolerant of alternative, conventional therapies’’ [2].
At that time, no efficacy or safety studies had been con-
ducted with tacrolimus in infants, and the approved indi-
cation was limited to patients at least 2 years of age. One
year later, in December 2001, pimecrolimus cream was
approved with a similar indication for mild-to-moderate
AD with similar warnings and contraindications based on
pharmacological class [3]. In contrast to tacrolimus, data
demonstrating the safety and efficacy of pimecrolimus
were available at the time of application for 436 infants
who had participated in clinical trials. On the basis of the
‘‘disproportionately higher incidence of adverse events,
particularly viral infections in infants,’’ seen in these trials,
the approved indication was limited to patients 2 years of
age and older. To further investigate the long-term safety
of both drugs, the FDA requested post-approval commit-
ments from both companies to establish pediatric registries
[4, 5].
At the time of drug approval, the FDA requested that
Astellas perform additional studies of topical tacrolimus
including: a retrospective analysis to explore any demo-
graphic and disease factors possibly associated with persis-
tently detectable blood concentrations [6]; bioavailability of
0.03 and 0.1 % ointments following long-term intermittent
treatment of AD [7]; and pharmacokinetics of 0.03 % oint-
ment in patients 2–5 years of age with moderate-to-severe
AD [7].
Upon pimecrolimus cream approval, the FDA also
requested that Novartis conduct two case-control epide-
miological studies to assess the risk of non-melanoma [8]
and melanoma skin cancers (protocol under FDA review)
in adults; a controlled safety and efficacy study in HIV-
positive patients; and a pregnancy registry. The last two
requests were waived/fulfilled via labeling change or pro-
vision of additional preclinical data. In addition, Novartis
initiated two ambitious long-term randomized clinical
studies to assess the effects of pimecrolimus cream in
infants as young as 3 months of age: a 6-year study
(N = 1,091) designed to evaluate long-term safety and the
impact of AD treatment on the progression of atopy; and a
5-year study (N = 2,418) designed to evaluate long-term
safety including growth velocity and immune system
development effects [9–13].
In October 2003, the FDA Pediatric Advisory Com-
mittee (PAC) met to review the products’ registry proto-
cols. However, the focus of the meeting was shifted by
recognition of increasing off-label use among infants
younger than 2 years of age (11 % of all TCI prescriptions
by the end of 2003; Fig. 1) [14] as well as by malignancy
reports made to the FDA’s adverse event reporting system
(AERS): two reports for pimecrolimus cream and five for
tacrolimus ointment. Following this meeting, two 10-year
prospective registries (planned N = 8,000 for each) were
created to assess the risk of malignancies in children with
tacrolimus ointment [A Prospective Pediatric Longitudinal
Evaluation to Assess the Long-Term Safety (APPLES) of
tacrolimus ointment for the treatment of AD] and pime-
crolimus cream [Pediatric Eczema Elective Registry
(PEER)]. APPLES includes patients no older than 16 years
of age and was initiated in 2005; PEER includes patients
2–17 years of age and was initiated in 2004.
The PAC convened 15 months later in February 2005 to
review the results of a newly completed oral carcinoge-
nicity study conducted in monkeys (the results of which are
discussed in detail in Sect. 3.1) as well as additional AERS
malignancy reports. The concerns of the PAC were ele-
vated in part by the manufacturers’ marketing efforts,
escalating TCI sales, and a higher rate of off-label use. On
the basis of the recommendation made at this meeting, the
FDA issued a public health advisory in March 2005 and a
requirement in January 2006 for revised labeling for both
products to include a boxed warning (‘black box’) and
medication guide (‘patient medi guide’) to address a the-
oretical risk of lymphoma and to emphasize that the safety
of long-term continuous use and use in patients 2 years of
age and younger had not been established [14, 15]. In
addition, the indications were modified to specify that TCIs
are ‘‘second-line [emphasis added] therapy for short-term
and non-continuous chronic treatment…of [AD] in non-
immunocompromised adults and children [C2 years of
age] who have failed to respond adequately to other topical
prescription treatments, or when those treatments are not
advisable’’ [3, 16]. This was the first time that the FDA
required that a boxed warning be issued on the basis of a
theoretical risk rather than proven safety concerns.
At subsequent meetings held in March 2010 and May
2011, the PAC reviewed post-marketing surveillance
(PMS) and epidemiological data for both drugs and found
it to be inconclusive with regards to both long-term safety
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concerns and malignancy risk [17, 18]. At both meetings,
the committee requested that the FDA continue to monitor
the literature, AERS, and product registries and maintain
the boxed warning until conclusive evidence was found
[18]. In light of these inconclusive findings, this re-exam-
ination of a possible link between TCI use and lymphoma
was undertaken.
2.2 Response from the Public and the Medical
Community
News coverage of the boxed warnings was widespread,
with stories appearing in notable publications, including
USA Today [19], Washington Post [20], BBC News [21],
and Consumer Reports [22]. The resulting patient concerns
led some patients and caregivers to dispose of their TCIs
and opt for other treatments or forgo treatment altogether.
Law firms began posting websites dedicated to soliciting
litigations against the makers of TCIs [23–27], further
adding to the anxiety among patients and caregivers.
Members of the medical community criticized the
FDA’s action and suggested that an unintended result was
to jeopardize the chances of ever clarifying the risks due to
decreased participation in clinical trials [28]. Some argued
that the FDA did not fairly weigh the data with respect to
low systemic exposure seen in humans, lack of cancer
adverse events in clinical studies, overall low rate of
malignancy reports, and lack of evidence for systemic
immune suppression with topical application of market
formulations in preclinical studies. Critics also argued that
the FDA overlooked the unmet medical need for these
agents as an alternative to topical corticosteroids, espe-
cially for infants and patients with facial involvement [28–
42]. Furthermore, some members of the medical commu-
nity questioned the plausibility of a biological link between
immunosuppression and the types of cancers observed [40–
42]. On the other hand, the FDA did not rescind either
drug’s approval or request the termination of any of the
ongoing clinical trials for either of these drugs.
2.3 Consequences of the Boxed Warning
As might be expected, TCI sales and off-label use among
infants decreased dramatically within a year of the public
health advisory (Figs. 1, 2). Payers responded to the boxed
warning by creating hurdles for both healthcare providers
and patients including limiting reimbursement, changing
formulary status, and/or requiring pre-authorization or
step-edits. Thereafter, sales of pimecrolimus cream con-
tinued to decline, possibly due to curtailed marketing
efforts by Novartis. On the other hand, sales of tacrolimus
ointment slightly increased despite little change in mar-
keting efforts by Astellas. However, a survey conducted
within 2 years after the labeling change reflected a negative
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March 2005
Fig. 1 US pimecrolimus cream and tacrolimus ointment prescrip-
tions (2002–2008). Interval for each year is January 1–December 31
except where noted. Values are percent of prescriptions dispensed for
infants (\2 years of age). Data source (2004–2008): SDI Vector
One National in briefing document from Patty Greene, Drug Use
Data Analyst, Division of Epidemiology, Office of Surveillance and
Epidemiology, FDA Center for Drug Evaluation and Research. BPCA
drug use review: Comparison of Elidel cream and Protopic
ointment utilization trends following 2006 labeling changes, 17 July
2009. Available from http://www.fda.gov/downloads/AdvisoryCom
mittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/
UCM204723.pdf. Accessed 2 April 2012. Data source (2002–2003):
IMS Health National Prescription Audit PlusTM in briefing document
from David Moeny, Pharmacist/Drug Use Specialist, Division of
Surveillance, Research and Communication Support, FDA Center for
Drug Evaluation and Research. Pediatric drug use analysis for topical
calcineurin inhibitors, 16 July 2004. Available from http://www.fda.
gov/ohrms/dockets/ac/05/briefing/2005-4089b2_01_05_Cleared%20
version%20Elidel-Protopic%20Drug%20Use%20Review%20D0403
89%207-2004.pdf. Accessed 23 May 2012. aInterval is June 1–May 31
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impact on long-term control among a significant minority
of patients. In place of TCIs, 35 % of these dermatologists
prescribed chronic topical corticosteroids; 12 % systemic
corticosteroids; 4 % cyclosporine; 4 % other systemic
immunosuppressants; and 20 % ultraviolet (UV) B or
psoralen plus UVA for AD [43].
3 Summary of the Evidence for Lymphoma Risk
3.1 Preclinical Data
At the time of approval for both drugs, malignancy signals
were detected in preclinical repeat-dose and carcinoge-
nicity studies only when systemic exposure to pimecroli-
mus or tacrolimus was sufficient for systemic immune
suppression (Table 1) [16, 44–46]. Given the known
malignancy risk with systemic immune suppressants
(which increases with the intensity and duration of immune
suppression) [47, 48], these results were not unexpected.
When systemic exposure was lower (drug given to animals
in their feed or topically applied using marketed formula-
tion), there were no neoplastic findings. In human studies
using topical administration (discussed in detail in
Sect. 4.5.1), systemic exposure is minimal.
The most common forms of malignancy seen in trans-
plant patients treated with systemic (oral or intravenous)
tacrolimus for graph-versus-host prophylaxis are skin
carcinomas and non-Hodgkin’s lymphomas (NHL) asso-
ciated with Epstein–Barr virus infection, which may
regress with treatment discontinuation [47]. In order to
determine if systemically administered oral pimecrolimus
can act through a similar mechanism, a 39-week oral
(gavage) toxicity study was conducted in monkeys. The
results of this study, reviewed by the FDA in February
2005, confirmed that oral pimecrolimus, given at doses
sufficient to result in systemic immune suppression (*30-
fold greater than the maximal exposure in humans with
topical application), can elicit lymphomas associated with
Epstein–Barr-like primate viruses similar to oral tacrolimus
[49]. These results were cited as part of the basis for the
boxed warning requirement for topical application [14, 50]
despite the fact that administration was oral rather than
topical and that evidence of systemic immune suppression
was not detected following topical administration.
3.2 Epidemiological Data
The literature review considered at the March 2010 PAC
meeting [51, 52] included conflicting data, summarized by
Tennis et al. [53]. In comparison to untreated AD patients,
Hui et al. [54] reported an increased risk of T cell lym-
phoma among tacrolimus ointment users (hazard ratio
[95 % CI]; 3.13 [1.41–6.94]), but not among pimecrolimus
cream users [1.86 (0.71–4.87)]. On the other hand, Arel-




































Fig. 2 Worldwide pimecrolimus cream and tacrolimus ointment
sales (2000–2011). Data source for pimecrolimus cream: Novartis
2002–2003 corporate annual reports. Available from http://www
unglobalcompact.org/participant/7016-Novartis-International-AG.
Accessed 2 April 2012; Novartis 2004–2008 corporate annual reports.
Available from http://www.novartis.com/newsroom/corporate-publi
cations/archive.shtml. Accessed 2 April 2012. Elidel worldwide
sales 2009–2011. Available from http://www.evaluatepharma.com/
Universal/View.aspx?type=Search&query=elidel. Accessed 29 March
2012. Data source for tacrolimus ointment: Astellas and Fujisawa
2001–2011 corporate annual reports. Available from http://www.
astellas.com/en/ir/library/annual_report.html. Accessed 2 April 2012.
(Using yearly conversion rates available from http://www.mac.
doc.gov/japan-korea/statistics/exchange.htm. Accessed 29 March
2012.) aFujisawa merged with Yamanouchi to become Astellas in
2004. bNovartis promotion scaled back Q1 2007, ceased Q3 2007.
cMeda acquired global rights to pimecrolimus cream Q2 2011 and
immediately licensed North American rights to Valeant
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Table 1 Relevant repeat-dose toxicity and carcinogenicity studies in animals as reviewed by the FDA (at approval)







oral (in feed) tacrolimus in
CD-1 miceb [16, 44]




oral (in feed) tacrolimus
in CD ratsb [16, 44]








The increased incidence of pleomorphic and
undifferentiated lymphomas are probably
due to the established pharmacologic effect
of tacrolimus, but the safety factor is
sufficient that ‘‘human patients would not




• Topical tacrolimus ointment 0.1 % was
associated with a statistically significant
increase in the incidence of pleomorphic
lymphoma (males and females) and
undifferentiated lymphoma (females) mostly
of B cell type
• No skin carcinomas were noted
Pimecrolimus [45, 46]
13-week toxicity of topical
pimecrolimus in ethanol
in CD-1 mice
The increased incidence of pleomorphic
lymphomas observed in this study may be
related to the pharmacological action of and








• Topical pimecrolimus 25 and 50 mg/kg/day
were associated with lymphoproliferative
changes, including malignancies
Oncogenicity of oral (gavage)
pimecrolimus in CD-l
mice for their life-span
The increased incidence of malignant
lymphoma was most likely a consequence of
systemic immunosuppression, but the safety







• Oral pimecrolimus 45 mg/kg/day was
associated with a statistically significant
increase in the incidence of follicular center
cell lymphoma, pleomorphic lymphoma, and




in Wistar rats (2 replicates)
The increased incidence of benign thymoma is
a significant finding but may not be relevant
to humans; the safety factor for females is







• Oral pimecrolimus 5 mg/kg/day (males) and
10 mg/kg/day (males and females) were
associated with a ‘‘biologically significant’’





The increased incidence of follicular cell
adenoma of the thyroid is a significant
finding but may not be relevant to humans;
the safety margin is not as great as noted in
other carcinogenicity studies, but since the
highest feasible dose was used, the study was
considered adequate






• A statistically significant increase in the
incidence of follicular cell adenoma in the
thyroid in all topical pimecrolimus cream
dose groups (0.2, 0.6, and 1.0 %) was noted
in males onlyd
• A slight (non-significant) increase in benign
thymoma was seen in males at all doses and
in females at the 0.2 % dose levele
• Non-neoplastic minimal-to-moderate
application site epithelial hyperplasia was
noted for both pimecrolimus cream and
vehicle; this was attributed to vehicle effects
• No lymphomas were noted
AUC area under concentration–time curve, NA not available, NOAEL no observed adverse effect level
a AUC is based on NOAEL unless otherwise noted; safety margin is in comparison to highest AUC seen with topical administration in humans
b Both the mouse and rat oral (in feed) studies were deemed as inadequate because of inadequate duration and low systemic exposure; however, since
these studies are heavily referenced in the FDA toxicology review, they are included in this table
c No malignancies were found in an additional 104-week carcinogenicity study of topical pimecrolimus in ethanol in CD-1 mice; however, the study was
deemed unacceptable by the FDA because of inadequate high dose and is not included in this table
d Male rats are more sensitive to thyroid effects than female rats or humans because of lower T4 hormone levels; this finding may not be relevant to
humans
e Values fell within the historical range for Wistar rats and/or showed no dose dependence; this finding was determined to be not significant
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(pimecrolimus cream or tacrolimus ointment) and lym-
phoma of any type (adjusted odds ratio [95 % CI]; 0.82
[0.42–1.61] and 0.79 [0.37–1.71], respectively) compared
with untreated AD patients. Schneeweiss et al. [56] also
report no significant increase in risk for lymphoma of any
type (rate ratio [95 % CI]; pimecrolimus cream: 1.79
[0.92–3.48]; tacrolimus ointment: 1.97 [0.87–4.50],
respectively) nor for cutaneous lymphomas (1.49
[0.36–6.24]; 2.53 [0.51–12.6], respectively) when TCI
users were compared with untreated AD patients. As with
all retrospective studies, each of these reports has signifi-
cant limitations, including low numbers of pediatric
patients, short duration, potential association between AD
and lymphoma, no assessment by lymphoma subtype,
exclusion of a lag period, and lack of case verification.
A full report of an additional long-term study was
available for the May 2011 PAC meeting [52]. This study
found no evidence for increased risk of lymphoma of any
type for the overall population (625,915 patients; adjusted
odds ratio [95 % CI]; pimecrolimus cream: 0.76
[0.54–1.08]; tacrolimus ointment: 1.24 [0.80–1.91]) or
among those patients younger than 20 years of age
(396,069 patients; pimecrolimus cream: 0.64 [0.34–1.21];
tacrolimus ointment: 0.96 [0.38–2.45]) compared with
untreated AD patients (patients were followed from
6 months to over 10 years). Among patients exposed to the
highest cumulative dose of tacrolimus ointment (C0.10 g),
the risk of lymphoma was significantly increased (2.08
[1.24–3.49]); however, no association was evident for
pimecrolimus cream. When T cell lymphomas were evaluated
alone, they found an increased risk of T cell lymphoma among
tacrolimus ointment users (4.95 [1.86–13.19]), which was
dose-dependent (\0.03 g: 4.27 [0.24–75.49]; C0.03 to
\0.06 g: 5.36 [0.78–37.05]; C0.06 to \0.10 g: 6.03
[1.31–27.70]; C0.10 g; 12.76 [3.35–48.68]). T cell lymphoma
risk was not elevated among pimecrolimus cream users (0.85
[0.25–2.90]) and showed no dose-dependence. Dose-depen-
dence results for T cell lymphoma should be interpreted
with caution, however, because of the low number of cases
in each category.
3.3 Clinical Databases
Relative cancer risk may be best appreciated by comparing
the actual number of reports in the entire exposed popu-
lation compared with the general population. In order to
make such a comparison, the cumulative worldwide
exposure was calculated by dividing the total amount (in
grams) of cream or ointment sold worldwide since launch by
the average amount of drug dispensed per year per patient in
the USA to obtain cumulative ‘patient-years’ (PY) of expo-
sure (Eq. 1). Thus, cumulative exposure, expressed as PY
accounts not only for the number of patients exposed but also
for duration of exposure. This method assumes constant dis-
tribution of tube sizes and number of ‘fills’ over time, in dif-
ferent countries, and for all age ranges.
Amount sold worldwide since launch ðgÞ
Average amount dispensed ðg/patient/yearÞ
¼ Cumulative exposure ðPYÞ ð1Þ
The number of reports that would be expected in the
general population (of similar age range) over the same
duration of observation (PY) was calculated on the basis of
age-adjusted incidences (per 100,000 PY) found in the
Surveillance, Epidemiology and End Results (SEER)
database (Eq. 2). In comparing these numbers, the rate of
malignancies and lymphomas with TCIs observed in
several clinical databases, including AERS, is similar to
or lower than the rate seen in the general population
(Table 2) [57–65]. In cases where only the number of
exposed patients is known (e.g., sponsored clinical trials
databases), and no information is available about the
duration of exposure, the expected number of malignancies
cannot be calculated in a manner that would allow for a
comparison across different study durations.
Ageadjusted SEER incidence
100;000 ðPY) cumulative exposure ðPYÞ
¼Expected reports ð2Þ
4 Critical Evaluation of the Evidence
A number of generally confounding factors must be con-
sidered when evaluating the strength of the evidence that
led to the FDA decision to apply the boxed warning—the
difficulty in assessing the risk of rare events, possible
confounding effects of disease state and severity, and a
consideration of risks and benefits across a number of
alternative therapies. Confounding factors specific to this
examination include the relative importance of preclinical
versus clinical data and the intrinsic properties of each of
the compounds.
4.1 Inherent Difficulties in Assessing the Risk of Rare
Events
Assessing risk based on spontaneous adverse event reports
(such as AERS) is complicated because of variable under-
reporting, indeterminate population size, and inconsistent
data quality, especially for details on drug exposure and
underlying diseases [66]. Spontaneous reporting might be
especially problematic for adverse events with long latency
times. Adverse events are believed to be under-reported to
the FDA by a factor of as much as 10 and the reporting rate
changes for the same product over time, with new and
168 E. C. Siegfried et al.
highly publicized drugs susceptible to increased reporting
rates.
4.2 Confounding Factors: Disease State and Severity
The interpretation of results of studies examining risk
associated with TCI exposure alone may be challenging
because of several confounding factors. Namely, that AD
like psoriasis (another inflammatory skin disease) may be
independently associated with a risk of developing lym-
phoma, which increases with severity [53, 67–71]. On the
other hand, in some cases, cutaneous T cell lymphoma
may be misdiagnosed as AD (and treated as such) owing
to similar clinical signs and symptoms [29, 72–74]. In
Table 2 Actual number of malignancy and lymphoma (Hodgkin’s and Non-Hodgkin’s) reports in clinical databases compared with the expected
number of reports in the general population (based on SEER [57])















Sponsored Comparative Clinical Trials in AD[58]
(as of December 2005) (~4,200 pts) all ages 0 -- 0 -- 0 --
US Post-Marketing Surveillance (PMS)[59]
(as of December 2009)
~1,600,000c
(~927,000 pts) pediatric
d 18 276(267-285) NA -- NA --
US Post-Marketing Surveillance (PMS)[60]
(as of February 2005)
~3,000,000c
(~1,700,000 pts) all ages NA --
HL and NHL
Lymphomae
Actual Expected (95% CI)b
11 (incl. 6 CTCL,




(as of September 2010)
10,724








(as of May 2011)
~1,600,000c,g










Sponsored Controlled Clinical Trials in AD
(as of March 2011) (>55,000 pts) all ages 5 -- 0 -- 1 (CTCL) --
Worldwide Post-Marketing Surveillance (PMS)h
(as of March 2011) >19,000,000 all ages
i 163 86,720(86,447-86,995)




61j (incl. 8 CTCL,




(as of October 2011)
16,219








(as of May 2011) >9,000,000
l





TACROLIMUS OINTMENT & PIMECROLIMUS CREAM
AERS[62]
(as of May 2011) -- <16 7 -- 0 -- 1 --
APPLES and PEER are the ongoing 10-year prospective registries (planned N = 8,000 for each) designed to assess the risk of malignancies in
children
AD atopic dermatitis, AERS FDA’s adverse event reporting system, CI confidence interval, CTCL cutaneous T cell lymphoma, CT/BCL cutaneous
T cell and B cell lymphoma, HL Hodgkin lymphoma, incl. includes, NA not available, NHL non-Hodgkin lymphoma, pts patients, PY patient-
years, TCI topical calcineurin inhibitor, YO year olds, – not calculable
a Calculated by dividing the total amount (g) of cream or ointment sold worldwide since launch by the average amount of drug dispensed per year
per patient (g/year/patient)
b Estimated based on age-adjusted incidences (per 100,000 PY) for 2009 (the most recent estimate available) in the SEER database [57];
estimates were rounded to the nearest whole number unless estimate was \10, then estimate was rounded to the nearest tenth; Lower limits of
95 % confidence intervals were rounded to the next lower whole number, upper limits were rounded to the next higher whole number)
c Estimated by multiplying the approximate number of patients exposed by the factor (3,000,000 PY/1,700,000 patients) given in the Tacrolimus
Ointment February 2005 PAC Briefing Book [64]
d Age range not further specified
e Only incidence of overall lymphoma available
f Calculated by adding the expected (95 % CI) number of reports for HL and NHL to obtain expected (95 % CI) number of reports for all
lymphomas
g Based on exposure data as of December 2009, the most recent estimate available
h Includes clinical trial (solicited), spontaneous, and literature reports
i Actual reports were in patients ranging in age from 11 months to 70 years
j Includes 13 unspecified lymphomas
k Includes 4 unspecified lymphomas in patients \20 YO
l Calculated by multiplying the cumulative exposure (PY) by the proportion of prescriptions dispensed to \17 YO estimated using SDI Vector
One data from 2004 to 2008 [65] (assuming that number and distribution of prescriptions were similar between 2002–2003 and 2004 and
between 2009–2011 and 2008)
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addition, patients receiving TCIs as second-line therapy or
at higher doses may bias the patient population toward
more severe disease and greater exposure, thereby also
increasing the potential for misleading results.
4.3 Benefit–Risk Analysis: Considering Alternative
Therapies
In order to properly weigh the risks and benefits of AD
treatment, one must consider the benefits and adverse
effects of all possible treatments. Topical corticosteroids
(TCS) are the mainstay of treatment for AD flares. How-
ever, no TCSs are indicated for long-term ([4 weeks) use
and few are approved for patients younger than 2 years of age
[75] because of skin-thinning potential and rebound effects.
TCIs, on the other hand, have low atrophogenic potential [76]
and skin permeation (as discussed in Sect. 4.5.1) and can be
used for long periods, even on sensitive skin areas, without
risk of developing tachyphylaxis [77–86].
There are no preclinical carcinogenicity studies of TCS
due to rapid toxicity in mice and rats, although, as an
immune suppressant, there is a plausible link. In fact, other
alternative anti-inflammatory AD treatments (i.e., oral
corticosteroids, oral immunosuppressives, and photother-
apy) all carry a risk of cancer [42, 71], and malignancy risk
with TCS is unclear [56, 87–89].
4.4 Sufficient Evidence for TCI Boxed Warning?
According to FDA guidance, boxed warnings are ordinarily
applied when (a) there is an adverse reaction so serious in
proportion to the potential benefit from the drug (e.g., fatal,
life-threatening, or permanently disabling) that it is
essential that it be considered when assessing the benefit–
risk ratio of prescribing the drug; (b) there is a serious
adverse reaction that can be prevented or reduced in fre-
quency or severity by appropriate use of the drug (e.g.,
patient selection, careful monitoring, avoiding use in a
specific clinical situation); or (c) the FDA approved the
drug with restrictions to ensure safe use [90]. According to
the guidance, a boxed warning can also be used to highlight
information that is considered especially important to the
prescriber (e.g., reduced effectiveness in certain patient
populations). Boxed warnings are most often based on
observed serious adverse reactions (i.e., clinical data) or, in
some cases, based on anticipated adverse reactions [i.e., an
expected adverse reaction based on pharmacologic action
of the drug (preclinical data)]. Beach et al. [91] found that
over 80 % of boxed warnings (in the 1995 Physicians’
Desk Reference) were based on clinical data including
adverse event reports obtained through clinical trials and
spontaneous reports. Only 9 % of warnings were based on
‘other’ evidence.
The boxed warning for TCIs was implemented despite
the fact that ‘‘a causal relationship has not been estab-
lished’’ [3, 16]. While no specific risks have been identi-
fied, the label indicates that ‘‘long-term safety of topical
calcineurin inhibitors has not been established…[and] rare
cases of malignancy (e.g., skin and lymphoma) have been
reported in patients treated with [TCIs]’’ [3, 16]. In con-
trast, the boxed warning for long-acting b-agonists for
childhood asthma is based on data from large placebo-
controlled trials that showed an increase in asthma-related
deaths [92].
There is some precedent for removing a boxed warn-
ing based on differences in systemic exposure between
oral and topical formulations and/or new clinical data
[93–95]. Given the inconclusive nature of prior evidence,
the clinical value of TCIs, and the negative impact of
limiting patients’ access to TCIs, significant weight
should be given to more recent epidemiological and
clinical data when considering the ongoing need for the
boxed warning.
4.5 Justification for a Class Labeling?
The FDA applies pharmacological classes to drugs in order
to help prescribers avoid duplicative therapy and drug
interactions. In order to maintain consistency, the agency
considers applying warnings, contraindications, and boxed
warnings to all members of a pharmacological class;
however, it does allow for these to be applied to a single
member of a class if the benefit–risk ratio is shown to apply
to only one member [90]. Low systemic exposure with
TCIs and striking differences between pimecrolimus cream
and tacrolimus ointment in terms of pharmacology and
clinical development programs might justify reconsidera-
tion of class labeling and/or warnings.
4.5.1 Low Systemic Exposure
Many studies with both pimecrolimus cream and tacroli-
mus ointment have shown systemic exposure to be low
after topical treatment in AD patients as young as 3 months
of age [7, 96–106]. In a head-to-head comparison study, the
highest blood concentrations detected in adults with mod-
erate-to-severe AD were 1.51 ng/mL in the pimecrolimus
cream group and 2.39 ng/mL in the tacrolimus ointment
group, both of which are substantially below target trough
concentrations for systemic immunosuppression for ta-
crolimus (5–20 ng/mL) in transplant patients [107]. In
infants, blood concentrations are similar to those seen in
adults with no evidence of accumulation for up to 1 year
[101–106]. The highest blood concentrations reported for
infants with pimecrolimus cream 1 % range from 1.8 to
4.14 ng/mL [101–105] and the average maximum
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concentration with tacrolimus ointment 0.03 % was 3 % of
that observed in pediatric liver-transplant patients receiving
oral tacrolimus [106].
In vitro skin penetration (into) for each compound is
approximately equal, but skin permeation (through) is greater
for tacrolimus ointment than pimecrolimus cream [108, 109].
When comparing relative permeation in normal versus
inflamed or corticosteroid-pretreated skin, both compounds
permeated inflamed and corticosteroid-pretreated skin to a
greater extent (up to a factor of 6 times greater than normal
skin) [108]. Thus, exposure to TCIs is self-limiting—as skin
barrier function is restored, exposure decreases. There is also
the argument that pediatric patients may have greater systemic
exposure because of their greater body surface area to weight
ratio. In the head-to-head trial, when blood concentrations after
tacrolimus ointment application were analyzed by total body
surface area (TBSA) affected by AD, they were detectable in
more patients as TBSA affected by AD increased [107].
4.5.2 Differences in Pharmacology
Unlike tacrolimus, which was originally developed for its
antirejection activity, pimecrolimus was developed spe-
cifically to target inflammatory skin diseases on the basis of
its pharmacology [110]. After oral administration in rats,
skin concentrations of pimecrolimus were consistently
greater (twofold) than that of tacrolimus whereas in other
tissues tested (blood, lymph nodes), concentrations of
tacrolimus were greater (6-fold and 50-fold, respectively)
[111]. In several animal models, pimecrolimus demon-
strated much lower immunosuppressive potential than
tacrolimus [1, 110, 112–115].
4.5.3 Differences in Clinical Programs
In addition, there are substantial differences in the number
of patients studied (and duration of treatment) with each
drug (Table 3) [63, 81, 116–118]. At the time of approval,
pimecrolimus cream had been studied in more pediatric
patients, including infants, for significantly longer dura-
tions, yet the indications for both drugs in these regards are
remarkably similar.
5 Implications for Daily Practice
5.1 Increased Burden on Medical Providers and their
Patients
Practicing physicians and their office staff bear the bulk of
administrative burden generated by the boxed warning,
while patients assume additional personal and financial
burden. In response to the warning, third-party payers
restricted off-label access to TCIs for children with con-
ditions other than TCS-failing AD, and for all infants. Most
third-party payers require time-consuming prior authori-
zation for all TCI prescriptions. In many states, Medicaid-
insured children have no access to these corticosteroid-
sparing medications [119] based on disease and age-spe-
cific labeling, amounting to discriminatory denials. Some
physicians may be hesitant to prescribe TCIs because of a
higher perceived medicolegal liability [120].
5.2 Consequences of Inaccurate Diagnosis
Cutaneous T cell lymphoma is a chronic condition with
insidious onset that may be misdiagnosed as AD, compli-
cating assessment of a true lymphoma risk associated with
TCIs.
5.3 Consequences of Inadequate Treatment
Active AD can have significant negative impact on quality of
life for patients and their caregivers. Adequate treatment has
been shown to significantly improve quality of life and
patient satisfaction [121, 122]. In addition, early disease
control may slow or prevent the ‘‘atopic march’’ to sub-
sequent allergic rhinitis, food allergy, and asthma [123].
Suboptimal management of AD leads to more frequent flares
and greater likelihood of exposure to medications like sys-
temic corticosteroids, cyclosporine, or other immunosup-
pressants with higher toxicity risks [42]. And in contrast to
frequent application of TCS, daily maintenance therapy with
TCIs does not interfere with skin barrier integrity or enhance
percutaneous absorption. Recommendations to limit expo-
sure to topical therapy with TCIs places disproportionate
importance on theoretical drug-related risks compared with
well-established risks of chronic skin disease.
In addition, the costs of inadequately treated AD are
substantial [124–127]. Dermatology is among the most dif-
ficult subspecialty to gain access to for publically insured
children [128]. The frequency of emergency department
(ED) visits for AD observed in one Midwest urban hospital
suggests restricted access to outpatient care and suboptimal
maintenance treatment, adding significant cost [119].
Emergency medicine providers receive limited training in
the management of dermatological issues [119, 129]. Fur-
thermore, prescription assistance programs (including the
Allergy and Asthma Foundation, the Health Well Founda-
tion, and the Chronic Disease Fund) do not include AD as an
eligible indication.
5.4 Optimal Use of TCIs
Most treatment algorithms recommend regular use of
emollients for control of dry skin with short-term TCS for
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treatment of AD flares. Under certain circumstances, TCIs
are a more appropriate first-line choice and/or useful
adjunct to TCS.
1. As a corticosteroid-sparing agent: Reducing the risks
of chronic TCS exposure is important, especially in
children treated with intranasal, inhaled, or systemic
corticosteroids for other atopic diseases such as asthma
or allergic rhinitis. The corticosteroid-sparing effect of
pimecrolimus cream has been demonstrated in clinical
trials [77–79, 130–134]. A reduced number of flares
and prolonged time-to-flare quantified in tacrolimus
ointment clinical trials also supports a corticosteroid-
sparing effect [135–140].
2. To treat face and skin fold disease: Skin atrophy,
perioral dermatitis, and increased percutaneous absorp-
tion are TCS risks prompting greatest concern in
patients with inflammatory skin disease involving
sensitive skin areas on the face, eyelids, and diaper
area. TCIs are well suited for use in these areas due to
low acnegenic and atrophogenic potential [76, 78, 83,
131, 141–152].
3. To simplify treatment regimens: Risks associated with
TCS use are highest with more potent products, especially
when applied to sensitive skin areas. To minimize these
risks, a popular approach is to recommend a two-drug
treatment regimen using a lower potency TCS on the face
and a higher potency product on the body. Patients are
Table 3 Pimecrolimus cream
and tacrolimus ointment clinical
development programs in atopic
dermatitis
NA not applicable
a Included in total adult
subjects despite overlapping age
range
b Time frames differ due to data
availability
c Includes duration of ongoing
registry studies (APPLES and
PEER); current duration of
exposure is shorter
d Interim analysis
Age Group Duration Subjects 
exposed
TACROLIMUS OINTMENT
Clinical trials reviewed at approval[116] 
Phase 3 controlled studies/pivotal
Children (2-15 years) 12 weeks 235
Adults (≥15 years) 12 weeks 202
Adults (≥16 years) 12 weeks 218
Phase 2 or 3 supportive safety
Children (3-6 years) 3 weeks 25
Children (6-16 years) 3 weeks 136
Adults (≥13 years) 3 weeks 159a
Adults (≥16 years) x 2 trials 1 week 226
Adults (≥16 years) x 4 trials 3 weeks 424
Adults (≥17 years) 3 weeks 20
Uncontrolled long-term safety
Children (2-15 years) 1 year 255
Adults (≥18 years) 1 year 318
Uncontrolled supportive safety
Adults (≥16 years) 2 years 569
Adults (≥18 years) 6 weeks 62
Total 2,849
Infants (<2 years) NA 0
Children (2-17 years) 3 weeks – 1 year 651
Adults (≥16 years) 1 week – 2 years 2,198
All clinical trials (as of May 2011b)
Total >36,000
Infants (<2 years)[81] ≤2 years ~50
Children (2-17 years)[117] ≤10 yearsd ~9,000
Adults (≥16 years)[117] ≤4 yearsd ~27,000
PIMECROLIMUS CREAM
Clinical trials reviewed at approval[118]
Phase 3 controlled studies/pivotal
Infants (<2 years) 26 weeks 123
Children (2-17 years) x 2 trials 26 weeks 267
Controlled supportive safety
Infants (<2 years) 6 monthsd 204
Children (2-17 years) 1 year 474
Adults (≥18 years) 1 year 328
Total 1,396
Infants (<2 years) 6 months – 1 year 327
Children (2-17 years) 6 months – 1 year 741
Adults (≥18 years) 1 year 328
All clinical trials (as of May 2010b)[63]
Total >55,000
Infants (<2 years) ≤6 years ~4,000
Children (2-17 years) ≤10 yearsd ~27,000
Adults (≥18 years) ≤3 years ~16,000
Other (≥3 months) ≤27 weeks ~8,000
Unspecified ≤3 years ~450
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often confused about the appropriate drug to use on the
affected sites, and monitoring the optimal quantity used
can also be complicated. Maintenance treatment with a
TCI requires use of only one product on all affected sites.
This not only simplifies treatment for the patient, but also
allows easier monitoring of drug quantity used over time.
4. For children who require daily treatment: Safety of
TCS has been studied for durations of no longer than
4 weeks for a limited number of products. In contrast,
safety of TCIs for durations of up to 1 year has been
documented in several prospective trials and registries
[83–86].
5. In patients who are TCS intolerant or dependent:
Well-described but under-recognized complications of
long-term use of TCS include delayed-type hypersen-
sitivity reactions, and rebound erythroderma. Neither
pimecrolimus cream nor tacrolimus ointment carry
these risks [150–153].
6. In patients with confirmed or suspected skin infection:
‘In cognito’ TCS-associated skin infections are another
complication that has been well-described but under-
appreciated [154]. The proposed mechanism of action
is via dendritic cells and antigen presentation [155]. In
contrast, TCIs do not affect the differentiation, matu-
ration, or function of dendritic cells [156–162].
Clinical trials have not identified an increased inci-
dence of skin infection for either TCI [82, 163, 164].
5.5 Effective Communication with Patient About
the Benefit–Risk Ratio
Even when a physician has weighed the risks and benefits
and determined that TCIs are the appropriate therapy for a
particular patient, an additional hurdle remains—discuss-
ing the boxed warning and medication guide. The ‘real’
risk of lymphoma with TCIs can be made more under-
standable to patients and caregivers by using some reas-
suring language. Suggested talking points include
1. The risk of lymphoma and other cancers is no higher
than what you see in the general population.
2. TCI molecules are about twice the size of corticoste-
roids, which makes it more difficult for them to
permeate the skin and cause systemic adverse effects.
3. All drugs, including TCIs and corticosteroids, have
risks and benefits.
4. The American Academy of Dermatology (AAD) and
other professional organizations do not support the
boxed warning.
5. Pharmacists and other healthcare professionals may
provide you with information that conflicts with what
we have discussed.
6. As your physician, I have carefully weighed the risks
and benefits of prescribing a TCI and feel that this drug
is well suited to manage your skin condition.
6 Conclusions
The TCIs were a welcome therapeutic option for the
management of AD when they were approved over
10 years ago, and they remain the only approved treatment
for long-term use in children 2 years of age and older.
Physicians quickly adopted the TCIs as a corticosteroid-
sparing adjunct to topical corticosteroids. Despite the
utility of TCIs, in January 2006, the FDA implemented a
boxed warning regarding the safety of long-term use and a
possible risk of lymphoma and limited the indication to
‘‘second-line therapy for the short-term and noncontinuous
chronic treatment of (mild-to-moderate or moderate-to-
severe AD) in nonimmunocompromised adults and chil-
dren (C2 years of age) who have failed to respond ade-
quately to other topical prescription treatments for (AD), or
when those treatments are not advisable’’ [3, 16]. This had
a significant impact on physician prescribing patterns and
patient access to these medications, leading to decreased
disease control and quality of life for patients and their
families. Many members of the medical community criti-
cized the actions of the FDA. They questioned the validity
of the boxed warning in large part because no definitive
human clinical trial data has demonstrated an increased risk
of malignancy with TCI exposure. In addition, several
epidemiological studies have shown no association
between TCI use and lymphoma risk in clinical practice,
and the incidences of malignancy and lymphoma in clinical
databases are below that of the general population. In
addition, a possible association between AD itself and
malignancy further erodes the basis for the warning. In
order to provide patients with optimal care, physicians
must have strategies for mitigating the impact of the boxed
warning on the quality and costs of AD management.
These include using TCIs appropriately as corticosteroid-
sparing agents and proactively communicating the rela-
tive risks and benefits of TCIs to patients and their
caregivers.
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